Skip to main content

NW London CLRN Primary Care Meeting

One of the organisations I work with is the North-West London Comprehensive Local Research Network (CLRN). The North-West CLRN is one of 25 CLRNs across England which form part of the NIHR Comprehensive Clinical Research Network (CCRN). The CCRN provides support for clinical trials and other well designed studies in all areas of disease and clinical need. A key role for the CLRN is providing infrastructure support for studies on the NIHR Portfolio. Part of this infrastructure support is in primary care. On October 7th 2009, the CLRN held a meeting with some of the local GPs and other primary care staff who collaborate with the CLRN.

One of the key points arising from the meeting was the need to get more NIHR portfolio studies active in primary care in NW London. IT issues were also discussed, particularly the need for expertise to run queries on GP Electronic Patient Record Systems such as EMIS and Vision. The need to continue reimbursement of practice expenses and also to offer additional value to GPs through involvement in research design and planning, access to training etc was also discussed, as was the high administrative workload in processing invoices for service support costs from a large number of general practices. We also discussed the need to review current levels of Clinical Study Officer (CSO) provision and to increase this if warranted by a rising number of accruals. The need for high-level GP/academic input to overcome some of the blocks that can be present in primary care research by liaising with relevant senior staff in PCTs and practices was also raised.

We will take forward these points in future CLRN meetings and with the Primary Care Research Network for Greater London (PCRN-GL).

Comments

Popular posts from this blog

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...

What makes a good doctor – and who gets to decide?

What Makes a Good Doctor? This is the question that Waseem Jerjes and I explore in the Journal of the Royal Society of Medicine . It is a key question that underpins the architecture of medical education, clinical practice, regulation, and professional identity. It cannot be answered by regulators, educators, or employers in isolation. It must be answered together – by doctors and patients – revisited throughout a career, and adapted as society and the profession change. Without that shared reflection, the danger is not simply disillusionment, but the erosion of the moral foundations of clinical work. As we enter an era when diagnosis will increasingly involve artificial intelligence and when performance metrics reward volume over value, reclaiming this question as a professional one is imperative. The integrity of our institutions – and of the practitioners within them – depends on reimagining excellence in inclusive, relational terms. A good doctor is not a flawless technician or a f...